Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Aug 08, 2022 11:44am
217 Views
Post# 34878851

RE:Share price

RE:Share priceOperating costs last quarter were $2.6 million. Total operating costs of $9.2 million for full 2021.

If they were able to cut costs and/or bring in enough revenues to stay neutral.  Say $2-2.2 million in revenues and cutting costs or $3 million in revenues with existing costs, either way that would be a very big step.  With annual revenues at $10-12 million while remaining cash flow positive, that would value the company in the $60-80 million range.  

If they had to do some creative financing or internal funding that we just haven't learned about yet, well that's a different story but it should still value the company higher than where it's sitting now at $11 million.

Q2 results are due Aug 15 by midnight which likely means after market closes on the Monday.  I assume we will hear soon about a 2nd quarter conference call for Tuesday Aug 16 before market opens.



brad129 wrote: If they had $600k end of last quarter and have 4-600k end of this quarter, where would the stock head, up or down? Hahaha


<< Previous
Bullboard Posts
Next >>